Market closed
Marinus Pharmaceuticals/$MRNS
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Marinus Pharmaceuticals
Marinus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing innovative therapeutics to treat epilepsy and neuropsychiatric disorders. Marinus manages the business in one segment, which is the identification and development of neuropsychiatric therapeutics. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19-RE.
Ticker
$MRNS
Sector
Trading on
Industry
Pharmaceuticals
Headquarters
Employees
166
Website
MRNS Metrics
BasicAdvanced
$16M
Market cap
-
P/E ratio
-$2.47
EPS
1.26
Beta
-
Dividend rate
Price and volume
Market cap
$16M
Beta
1.26
52-week high
$11.26
52-week low
$0.26
Average daily volume
1.3M
Financial strength
Current ratio
1.664
Quick ratio
1.334
Long term debt to equity
-143.632
Total debt to equity
-143.632
Interest coverage (TTM)
-7.17%
Management effectiveness
Return on assets (TTM)
-57.97%
Return on equity (TTM)
2,302.56%
Valuation
Price to revenue (TTM)
0.519
Price to book
-0.24
Price to tangible book (TTM)
-0.24
Price to free cash flow (TTM)
-0.141
Growth
Revenue change (TTM)
1.63%
Earnings per share change (TTM)
-6.22%
3-year revenue growth (CAGR)
26.97%
3-year earnings per share growth (CAGR)
-0.18%
What the Analysts think about MRNS
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Marinus Pharmaceuticals stock.
MRNS Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
MRNS Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
MRNS News
AllArticlesVideos
3 Micro-Caps Set for Major Moves: Balancing Risk and Opportunity
Benzinga·2 months ago
Marinus Pharmaceuticals Further Strengthens Intellectual Property Estate with Method of Treatment Patent for ZTALMY® Titration Regimens
Business Wire·2 months ago
3 Micro-Caps Set for Major Moves: Balancing Risk and Opportunity
MarketBeat·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Marinus Pharmaceuticals stock?
Marinus Pharmaceuticals (MRNS) has a market cap of $16M as of December 13, 2024.
What is the P/E ratio for Marinus Pharmaceuticals stock?
The price to earnings (P/E) ratio for Marinus Pharmaceuticals (MRNS) stock is 0 as of December 13, 2024.
Does Marinus Pharmaceuticals stock pay dividends?
No, Marinus Pharmaceuticals (MRNS) stock does not pay dividends to its shareholders as of December 13, 2024.
When is the next Marinus Pharmaceuticals dividend payment date?
Marinus Pharmaceuticals (MRNS) stock does not pay dividends to its shareholders.
What is the beta indicator for Marinus Pharmaceuticals?
Marinus Pharmaceuticals (MRNS) has a beta rating of 1.26. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.